Macrophages execute core functions in maintaining tissue homeostasis, in which their extensive plasticity permits a spectrum of functions from tissue remodeling to immune defense. However, perturbations to tissue-resident macrophages during disease, and the subsequent emergence of monocyte-derived macrophages, can hinder tissue recovery and promote further damage through inflammatory and fibrotic programs. Gaining a fundamental understanding of the critical pathways defining pathogenic macrophage populations enables the development of targeted therapeutic approaches to improve disease outcomes. In the setting of chronic graft-versus-host disease (cGVHD), which remains the major complication of allogeneic hematopoietic stem cell transplantation, colony-stimulating factor 1 (CSF1)–dependent donor-derived macrophages have been identified as key pathogenic mediators of fibrotic skin and lung disease. Antibody blockade of the CSF1 receptor (CSF1R) to induce macrophage depletion showed remarkable capacity to prevent fibrosis in preclinical models and has subsequently demonstrated impressive efficacy for improving cGVHD in ongoing clinical trials. Similarly, macrophage depletion approaches are currently under investigation for their potential to augment responses to immune checkpoint inhibition. Moreover, both monocyte and tissue-resident macrophage populations have recently been implicated as mediators of the numerous toxicities associated with chimeric antigen receptor T-cell therapy, further highlighting potential avenues of macrophage-based interventions to improve clinical outcomes. Herein, we examine the current literature on basic macrophage biology and contextualize this in the setting of cellular and immunotherapy. Additionally, we highlight mechanisms by which macrophages can be targeted, largely by interfering with the CSF1/CSF1R signaling axis, for therapeutic benefit in the context of both cellular and immunotherapy.
            Skip Nav Destination
            
        
            
    
 
    
    
    
        
                
        
    
        
    
    
        
    
        
                
    
                
            
            
        
                
                
    
 
    
    
         
    
    
    
  
        
            
        
    
    
 
    
        
                
    
        
    
        
            
                
            
        
        
        
    
        
    
        
                
            
 
    
        
    
 
    
                
                
                            
                        
                        
                                    
        
    
                
 
    
            
        
     
    
        
    
        
 
    
        
    
        
    
    
    
        
    
    
    
        
    
    
    
        
    
        
        
        
        
 
    
    
 
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
    
        
    
    
    
        
 
    
    
 
    
    
        
    
    
    
        
    
    
        
            
    
 
    
    
 
    
    
        
    
    
    
        
     
    
    
 
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
 
    
        
    
        
 
    
     
    
         
    
    
         
    
        
    
        REVIEW ARTICLE|
        March 6, 2025
    The contribution of the monocyte-macrophage lineage to immunotherapy outcomes Available to Purchase
                            
            Rachael C. Adams,
                    
    
        
    
        
    
                        
                
                
    Rachael C. Adams
    1Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
2Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
    
        Search for other works by this author on:
    
    
    
                            
            Kelli P. A. MacDonald,
                    
    
        
    
        
                        
                
                
    Kelli P. A. MacDonald
    1Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
    
        Search for other works by this author on:
    
    
    
                                Geoffrey R. Hill
                    
    
        
    
        
                        
                
    
    Geoffrey R. Hill
    2Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
    
        Search for other works by this author on:
    
    
    
Blood (2025) 145 (10): 1010–1021.
        
                    
                        Article history
                    
                    
                            
                                
                            
                                
                            
                                
                    
                
        Submitted:
                                September 5, 2024
                            Accepted:
                                November 4, 2024
                            First Edition:
                                November 22, 2024
                            Citation
  Rachael C. Adams, Kelli P. A. MacDonald, Geoffrey R. Hill; The contribution of the monocyte-macrophage lineage to immunotherapy outcomes. Blood 2025; 145 (10): 1010–1021. doi: https://doi.org/10.1182/blood.2024025680
Download citation file:
My Account
Sign In
            March 6 2025
        
    Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
 https://orcid.org/0000-0002-3248-587X
  https://orcid.org/0000-0002-3248-587X
        
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal